ImmunoPrecise Antibodies Ltd Forecast, price target & analysts
ImmunoPrecise Antibodies Ltd Target price 2025 - Analyst rating & recommendation
ImmunoPrecise Antibodies Ltd Classifications & Recommendation:
ImmunoPrecise Antibodies Ltd Price Target
| Target Price | $5.10 |
| Price | $1.72 |
| Potential |
196.51%
register free of charge
|
| Number of Estimates | 2 |
|
2 Analysts have issued a price target ImmunoPrecise Antibodies Ltd 2026 .
The average ImmunoPrecise Antibodies Ltd target price is $5.10.
This is
196.51%
register free of charge
$5.25
205.23%
register free of charge
$5.05
193.60%
register free of charge
|
|
| A rating was issued by 6 analysts: 5 Analysts recommend ImmunoPrecise Antibodies Ltd to buy, 1 to hold and 0 to sell. | |
| Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
|
Analyst Estimates: Analysts believe that the ImmunoPrecise Antibodies Ltd stock has an average upside potential 2026 of
196.51%
register free of charge
|
Sales and Margin forecast 2026, 2027 to 2032
| Apr '25 |
2026 Estimates |
|
|---|---|---|
| Revenue Million $ | 17.93 | 21.29 |
| 0.00% | 18.75% | |
| Net Margin | -123.31% | -24.01% |
| 11.22% | 80.53% |
3 Analysts have issued a sales forecast ImmunoPrecise Antibodies Ltd 2026 . The average ImmunoPrecise Antibodies Ltd sales estimate is
This results in the following potential growth metrics:
3 ImmunoPrecise Antibodies Ltd Analysts have issued a net profit forecast 2026. The average ImmunoPrecise Antibodies Ltd net profit estimate is
This results in the following potential growth metrics and future Net Margins:
Earnings per share, P/E ratio and EV/sales Estimates 2026, 2027 & 2028
| Apr '25 |
2026 Estimates |
|
|---|---|---|
| Earnings Per Share $ | -0.66 | -0.11 |
| 15.38% | 83.33% | |
| P/E | negative |
3 Analysts have issued a ImmunoPrecise Antibodies Ltd forecast for earnings per share. The average ImmunoPrecise Antibodies Ltd EPS is
This results in the following potential growth metrics and future valuations:
P/E ratio
| Current | -3.58 | 526.89% |
|---|---|---|
| 2027 |
38.82
349.97%
Unlock
|
|
ImmunoPrecise Antibodies Ltd...
Current ImmunoPrecise Antibodies Ltd Upgrades & Downgrades
| Analyst | Rating | Action | Date |
|---|---|---|---|
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Apr 11 2025 |
| Benchmark |
Locked
➜
Locked
|
Locked | Apr 01 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 31 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Mar 14 2025 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Dec 11 2024 |
| HC Wainwright & Co. |
Locked
➜
Locked
|
Locked | Sep 17 2024 |
| Analyst Rating | Date |
|---|---|
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Apr 11 2025 |
|
Locked
Benchmark:
Locked
➜
Locked
|
Apr 01 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 31 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Mar 14 2025 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Dec 11 2024 |
|
Locked
HC Wainwright & Co.:
Locked
➜
Locked
|
Sep 17 2024 |
Discover more stocks with a high price target
Register for Free
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.
